

PyNPase expression and increase the susceptibility of the tumor cells to 5'-dFurd. In the present study, we examined the ability of IL-12 to augment the antitumor activity of 5'-dFurd through the up-regulation of cytokines and PyNPase in murine tumor models

Results: 1) Administration of mL-12 increased tumor levels of mIFN- γ , mL-1 α and PyNPase activity. The tumor level of mIFN- γ was higher than that of the serum level, indicating that mIFN- γ was produced in the tumor tissue. 2) Increases in tumor levels of mIFN- γ and PyNPase by mL-12 were not observed in T-cell deficient mice, indicating that these processes were T-cell dependent. 3) Administration of mL-12 and 5'-dFurd in combination showed synergistic antitumor activity in the A755 mammary adenocarcinoma model. Furthermore, this combination induced remarkable prolongation of the survival and complete regression of the tumor.

Conclusion: IL-12, which up-regulate local cytokine production and PyNPase activity in the tumor tissues, would have additional therapeutic benefits in combination with 5'-dFurd, as well as in combination with capecitabine.

791

POSTER

PGP and growth factor expression is cell cycle dependent; Expression and function is modulated by sequential TMX and IFN

L. Seymour¹, W.R. Bezwoda². ¹Queens' University, Canada; ²Wits University, SA

Purpose: Tamoxifen (TMX) has been shown to have a number of clinically relevant effects on hormone receptor and growth factor expression as well as on p-glycoprotein (PGP) expression and function. Interferons (IFN), at least in vitro, may potentiate these effects.

Methods: The effects of TMX and α -IFN on cell kinetics, growth factor expression and PGP expression and function in MCF-7 and MCF-7^{mdr} cells were examined. Cells were cultured in indicator free RPMI and stripped FCS in the presence of α -IFN \pm TMX. Harvested cells were examined by immunocytochemistry (ICA) for ER, P24, PDGF, c-erbB-2 and PGP. Functional efflux and membrane vesicle studies were performed with ³H-vinblastine (VB) utilising standard methodology.

Results: Expression of ER, P24 and PDGF was cell cycle related. TMX was growth inhibitory and modestly increased P24, PGP and c-erbB2 expression. Preincubation of cells with α -IFN prior to TMX exposure potentiated the effects of TMX on growth inhibition, P24, c-erbB-2 and PGP expression, increased ER expression and led to decreased expression of PDGF. Short term exposure to TMX decreased VB efflux and was significantly increased by preincubation with α -IFN prior to the addition of TMX. The effects were ATP dependent, suggesting decreased efflux was due to modulation of PGP activity. TMX \pm α -IFN increased PGP expression, but decreased function suggesting possible competitive inhibition.

Conclusions: Sequential α -IFN and TMX increases ER, P24 and c-erbB2 expression, decreases expression of PDGF and partially reverses the MDR-1 phenotype in vitro. Clinical studies examining the role of TMX and α -IFN in modulation of MDR-1 mediated drug resistance are indicated.

792

POSTER

DNA alkylation and interstrand crosslinking by treosulfan

J.A. Hartley¹, C.C. O'Hare¹, J. Baumgart². ¹CRC Drug-DNA Interactions Research Group, Dept. Oncology UCL Medical School, 91 Riding House Street, London; ²Medac, Fehlandstrasse 3, D-20354 Hamburg, Germany

Purpose: The antitumour drug treosulfan (L-threitol 1,4-bis(methanesulfonyl), Ovastat) is used clinically primarily in the treatment of advanced ovarian cancer and the lack of significant non-haematological toxicity suggests treosulfan as a candidate for high dose chemotherapy regimens with autologous stem cell reinfusion. The present study investigates the molecular mechanism of action of treosulfan.

Methods: Cytotoxicity was assessed in human tumour cells using the MTT assay. DNA interstrand crosslinking was measured in plasmid DNA using an agarose gel based method and in cells using alkaline elution. DNA sequence specificity was measured using a Taq polymerase stop assay.

Results: The pH-dependent, non-enzymatic conversion of treosulfan to epoxide species is required for cytotoxicity *in vitro*. Alkylation and interstrand crosslinking of plasmid DNA is observed following treosulfan treatment, again produced via the active epoxide species. Alkylation is sequence specific occurring at guanine bases with a preference for runs of contiguous guanines, as observed previously with alkylating agents such as nitrogen mustards. In treosulfan-treated human leukaemic K562 cells DNA crosslinks form slowly, reaching a peak at approximately 24 hours. Incubation of cells with the pre-formed epoxides shows faster and more efficient crosslinking.

The sensitivity of cells to treosulfan was not determined by levels of either guanine-O6-alkyltransferase or glutathione.

Conclusion: The prodrug treosulfan acts as a DNA crosslinking agent following conversion to epoxide species.

793

POSTER

In vivo evaluation of the Irinotecan-oxaliplatin combination

M.C. Bissery, P. Vrignaud, F. Lavelle. Department of Oncology, Rhône-Poulenc Rorer S.A., 94403 Vitry-sur-Seine, France

Purpose: Irinotecan (Campto[®], CPT-11) and oxaliplatin (Eloxatine[®]) are two new agents approved for the treatment of colon cancer. The goal of this study was to evaluate them in combination in tumor bearing mice.

Methods: Dose-response studies were performed following the intermittent i.v. administration of irinotecan, oxaliplatin, and their simultaneous combination, to B6D2F₁ mice bearing subcutaneous Glasgow osteogenic sarcoma (GOS). This model was chosen as it was found the only model with similar sensitivity to both agents. Efficacy was determined at the highest non toxic dose in each arm of the trial. The end point used was the log cell kill (tumor growth delay in days/3.32 \times tumor doubling time in days).

Results: The single agents were found active at their respective highest non toxic dose, irinotecan: 349.8 mg/kg with a 2.1 log cell kill, and oxaliplatin: 10.2 mg/kg with a 2.3 log cell kill. Host recovery occurred within 10 and 6 days for Irinotecan and oxaliplatin, respectively. The optimal combination (irinotecan: 226.8 mg/kg and oxaliplatin: 10.8 mg/kg) was also very active with a 2.3 log cell kill. Full host recovery was obtained 10 days post therapy.

Conclusion: At equitoxic dosages, the simultaneous administration of i.v. irinotecan and oxaliplatin to GOS bearing mice produce a similar activity to that produced by each of the single agents.

794

POSTER

Kinetics of MTX-albumin conjugates in rats

A. Wunder¹, G. Stehle^{1,2}, H. Sinn¹, H.H. Schrenk¹, D. Hoff-Biederbeck², G. Hartung³, E. Frei⁴, W. Maier-Borst¹, D.L. Heene². ¹Dept Radiopharmacol. FS 5; ⁴Dept. Mol. Toxicol. FS 3, German Cancer Res. Center, HD; ²I. Dept. of Medicine, Faculty for Clin. Med. Mannheim, Univ. Heidelberg, Mannheim; ³III. Dept. of Medicine, Faculty for Clin. Med. Mannheim, Univ. Heidelberg, Mannheim, Germany

Pharmacokinetics, organ distribution and tumor uptake of methotrexate-albumin conjugates, denervated at a molar ratio of 1:1, were compared with the properties of the native carrier protein and with native MTX.

Methods and Results: Rats bearing W-256 tumors received iv injections of residualizingly radiolabeled MTX-albumin or of residualizingly radiolabeled albumin or tritiated MTX. Pharmacokinetics of all compounds were determined by radioactivity, MTX-albumin and MTX were also measured by an immunologic assay (EMIT MTX) in plasma. After tumor and organ removal uptake rates were recorded. The distribution pattern of MTX-albumin was identical with that of native albumin. Area under curve calculations for plasma concentrations of MTX-albumin exceeded those of MTX by 120 fold. After 1 h about 4.2% of the injected dose of MTX-albumin had accumulated in the tumor compared to 0.11% of MTX. After 24 h tumor uptake rate of MTX-albumin increased to about 14%, whereas MTX declined to 0.04%. The liver uptake rate was 7.6% for the conjugate and 1.8% for MTX after 24 h.

Conclusion: Conjugation of MTX to albumin will dramatically alter MTX pharmacokinetics. Advantages of MTX-albumin conjugates are a very long plasma presence comparable to native albumin and high tumor accumulation rates.

795

POSTER

Albumin catabolism by tumors

G. Stehle^{1,2}, H. Sinn¹, A. Wunder², H.H. Schrenk¹, E.A. Friedrich¹, G. Hartung³, F. Bader², W. Maier-Borst¹, D.L. Heene². ¹Dept Radiopharmacol. FS 5, German Cancer Res. Center, HD; ²I. Dept. of Medicine, Faculty for Clin. Med. Mannheim, Univ. Heidelberg, Mannheim; ³III. Dept. of Medicine, Faculty for Clin. Med. Mannheim, Univ. Heidelberg, Mannheim, Germany

Albumin dominates the nitrogen and energy resources in blood. However, only limited data is available on its accumulation and catabolism by tumors. This was caused by the lack of suitable radiolabels for long-term follow-up of protein catabolism *in vivo*. Conventional radiolabels like radiolodine are metabolically unstable. Tumors with high metabolic activity evade detection.